Background Mutations in BRCA1 or BRCA2 genes results in an elevated risk for developing
both breast and ovarian cancers over the lifetime of affected carriers. General surgeons may …

Increasing numbers of women experience early menopause due in part to surgical treatment
for benign gynecologic disorders and the rise in risk-reducing bilateral salpingo …

Background The cost-effectiveness of population-based panel testing for high-and moderate-
penetrance ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We …

Background: Previous studies have reported a breast cancer (BC) risk reduction of
approximately 50% after risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 …

Background: Population-based testing for BRCA1/2 mutations detects the high proportion of
carriers not identified by cancer family history (FH)–based testing. We compared the cost …

Purpose: Approximately 5–10% of patients who undergo genetic testing of BRCA1 and
BRCA2 receive a variant of unknown significance (VUS) result. The ambiguous nature of a …

Abstract BACKGROUND: For BRCA1/BRCA2 gene testing to benefit public health, mutation
carriers must initiate appropriate risk management strategies. There has been little research …

Several medical management approaches have been shown to be effective in preventing
breast cancer and detecting it early among women at elevated risk: 1) prophylactic …

Women who inherit a mutation in either the BRCA1 or BRCA2 gene have greatly elevated
lifetime risks of ovarian cancer, fallopian tube cancer and breast cancer. Preventive surgical …

Background. Inherited BRCA gene mutations convey a high risk for breast and ovarian
cancer, but current guidelines limit BRCA mutation testing to women with early-onset cancer …